Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
121.34
-1.60 (-1.30%)
At close: Nov 16, 2026, 4:00 PM EST
121.34
0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM EST

Haemonetics Statistics

Total Valuation

Haemonetics has a market cap or net worth of $5.53 billion. The enterprise value is $6.39 billion.

Market Cap5.53B
Enterprise Value 6.39B

Important Dates

The last earnings date was Thursday, November 5, 2026, before market open.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Haemonetics has 45.54 million shares outstanding. The number of shares has decreased by -5.39% in one year.

Current Share Class 45.54M
Shares Outstanding 45.54M
Shares Change (YoY) -5.39%
Shares Change (QoQ) +1.66%
Owned by Insiders (%) 1.30%
Owned by Institutions (%) 105.40%
Float 44.93M

Valuation Ratios

The trailing PE ratio is 54.21 and the forward PE ratio is 20.44. Haemonetics's PEG ratio is 1.82.

PE Ratio 54.21
Forward PE 20.44
PS Ratio 4.00
Forward PS 3.63
PB Ratio 6.23
P/TBV Ratio n/a
P/FCF Ratio 18.53
P/OCF Ratio 16.02
PEG Ratio 1.82
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.55, with an EV/FCF ratio of 21.41.

EV / Earnings 61.46
EV / Sales 4.62
EV / EBITDA 17.55
EV / EBIT 24.53
EV / FCF 21.41

Financial Position

The company has a current ratio of 2.84, with a Debt / Equity ratio of 1.25.

Current Ratio 2.84
Quick Ratio 1.62
Debt / Equity 1.25
Debt / EBITDA 3.00
Debt / FCF 3.77
Interest Coverage 7.44

Financial Efficiency

Return on equity (ROE) is 11.89% and return on invested capital (ROIC) is 10.75%.

Return on Equity (ROE) 11.89%
Return on Assets (ROA) 6.71%
Return on Invested Capital (ROIC) 10.75%
Return on Capital Employed (ROCE) 12.34%
Weighted Average Cost of Capital (WACC) 6.60%
Revenue Per Employee $459,441
Profits Per Employee $34,532
Employee Count3,009
Asset Turnover 0.57
Inventory Turnover 1.74

Taxes

In the past 12 months, Haemonetics has paid $38.10 million in taxes.

Income Tax 38.10M
Effective Tax Rate 26.83%

Stock Price Statistics

The stock price has increased by +65.11% in the last 52 weeks. The beta is 0.59, so Haemonetics's price volatility has been lower than the market average.

Beta (5Y) 0.59
52-Week Price Change +65.11%
50-Day Moving Average 113.68
200-Day Moving Average 81.54
Relative Strength Index (RSI) 55.29
Average Volume (20 Days) 683,903

Short Selling Information

The latest short interest is 3.60 million, so 7.90% of the outstanding shares have been sold short.

Short Interest 3.60M
Short Previous Month 3.04M
Short % of Shares Out 7.90%
Short % of Float 8.01%
Short Ratio (days to cover) 5.01

Income Statement

In the last 12 months, Haemonetics had revenue of $1.38 billion and earned $103.91 million in profits. Earnings per share was $2.24.

Revenue1.38B
Gross Profit 826.20M
Operating Income 260.39M
Pretax Income 142.01M
Net Income 103.91M
EBITDA 363.87M
EBIT 260.39M
Earnings Per Share (EPS) $2.24
Full Income Statement

Balance Sheet

The company has $262.91 million in cash and $1.12 billion in debt, with a net cash position of -$860.85 million or -$18.90 per share.

Cash & Cash Equivalents 262.91M
Total Debt 1.12B
Net Cash -860.85M
Net Cash Per Share -$18.90
Equity (Book Value) 898.50M
Book Value Per Share 19.74
Working Capital 554.69M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $344.93 million and capital expenditures -$46.69 million, giving a free cash flow of $298.24 million.

Operating Cash Flow 344.93M
Capital Expenditures -46.69M
Depreciation & Amortization 103.48M
Net Borrowing -106.25M
Free Cash Flow 298.24M
FCF Per Share $6.55
Full Cash Flow Statement

Margins

Gross margin is 59.76%, with operating and profit margins of 18.84% and 7.52%.

Gross Margin 59.76%
Operating Margin 18.84%
Pretax Margin 10.27%
Profit Margin 7.52%
EBITDA Margin 26.32%
EBIT Margin 18.84%
FCF Margin 21.57%

Dividends & Yields

Haemonetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield 5.39%
Shareholder Yield 5.39%
Earnings Yield 1.84%
FCF Yield 5.40%

Analyst Forecast

The average price target for Haemonetics is $147.18, which is 21.30% higher than the current price. The consensus rating is "Buy".

Price Target $147.18
Price Target Difference 21.30%
Analyst Consensus Buy
Analyst Count 12
Revenue Growth Forecast (3Y) 8.95%
EPS Growth Forecast (3Y) 13.13%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.

Last Split Date Dec 3, 2012
Split Type Forward
Split Ratio 2:1

Scores

Haemonetics has an Altman Z-Score of 2.73 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.73
Piotroski F-Score 7